Advertisement
Advertisement

NVCR

NVCR logo

NovoCure Limited Ordinary Shares

14.27
USD
Sponsored
+0.50
+3.63%
Jan 06, 15:19 UTC -5
Open

NVCR Earnings Reports

Positive Surprise Ratio

NVCR beat 23 of 40 last estimates.

57%

Next Report

Date of Next Report
Feb 23, 2026
Estimate for Q4 25 (Revenue/ EPS)
$172.30M
/
-$0.40
Implied change from Q3 25 (Revenue/ EPS)
+3.05%
/
+21.21%
Implied change from Q4 24 (Revenue/ EPS)
+6.84%
/
-34.43%

NovoCure Limited Ordinary Shares earnings per share and revenue

On Oct 30, 2025, NVCR reported earnings of -0.33 USD per share (EPS) for Q3 25, beating the estimate of -0.42 USD, resulting in a 23.15% surprise. Revenue reached 167.20 million, compared to an expected 162.37 million, with a 2.98% difference. The market reacted with a -4.90% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 10 analysts forecast an EPS of -0.40 USD, with revenue projected to reach 172.30 million USD, implying an increase of 21.21% EPS, and increase of 3.05% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Citius Oncology, Inc. Common Stock
Report Date
Dec 23, 2025 For Q4 25
Estimate
-$0.12
Actual
-$0.06
Surprise
+50.98%
FAQ
For Q3 2025, NovoCure Limited Ordinary Shares reported EPS of -$0.33, beating estimates by 23.15%, and revenue of $167.20M, 2.98% above expectations.
The stock price moved down -4.9%, changed from $13.48 before the earnings release to $12.82 the day after.
The next earning report is scheduled for Feb 23, 2026.
Based on 10 analysts, NovoCure Limited Ordinary Shares is expected to report EPS of -$0.40 and revenue of $172.30M for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement